Safety Assessment of Ubiquinol Acetate: Subchronic Toxicity and Genotoxicity Studies

Table 5

In vitro micronucleus test for ubiquinol acetate in cho-k1 cells.

SL No.	Treatment	Total Micronuclei with Binucleated scored	Total Binucleated scored	% Micronuclei
Treatment in absence of S9 (4 h)
1	Media control (HAM’s F12-K)	12	2000	0.60
2	Vehicle control (1 % Acetone)	17	2000	0.85
3	Mitomycin C at 0.5 μg/mL	188	2000	9.40
4	Ubiquinol acetate at 15.625 μg/mL	14	2000	0.70
5	Ubiquinol acetate at 31.25 μg/mL	14	2000	0.70
6	Ubiquinol acetate at 62.5 μg/mL^a	18	2000	0.90
Treatment in absence of S9 (24 h)
7	Media control (HAM’s F12-K)	16	2000	0.80
8	Vehicle control (1 % Acetone)	9	2000	0.45
9	Mitomycin C at 0.5 μg/mL	213	2000	10.65
10	Ubiquinol acetate at 15.625 μg/mL	17	2000	0.85
11	Ubiquinol acetate at 31.25 μg/mL	12	2000	0.60
12	Ubiquinol acetate at 62.5 μg/mL^a	11	2000	0.55
Treatment in presence of S9 (4 h)
13	Media control (HAM’s F12-K)	12	2000	0.60
14	Vehicle control (1 % Acetone)	10	2000	0.50
15	Cyclophosphamide at 0.5 μg/mL	144	2000	7.20
16	Ubiquinol acetate at 15.625 μg/mL	17	2000	0.85
17	Ubiquinol acetate at 31.25 μg/mL	13	2000	0.65
18	Ubiquinol acetate at 62.5 μg/mL^a	13	2000	0.65

‘a’ least insoluble concentration; % micronuclei is statistically increased compared to the vehicle control at p <0.05.